Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
25,974,026
-
Total 13F shares
-
204,702
-
Share change
-
+204,702
-
Total reported value
-
$2,282,195
-
Price per share
-
$11.15
-
Number of holders
-
10
-
Value change
-
+$2,282,196
-
Number of buys
-
10
Institutional Holders of Liminatus Pharma, Inc. - Common Stock, $0.0001 par value per share (LIMN) as of Q2 2025
As of 30 Jun 2025,
Liminatus Pharma, Inc. - Common Stock, $0.0001 par value per share (LIMN) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
204,702 shares.
The largest 10 holders included
VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, STATE STREET CORP, BlackRock, Inc., Royal Bank of Canada, Tower Research Capital LLC (TRC), BARCLAYS PLC, BANK OF AMERICA CORP /DE/, and SBI Securities Co., Ltd..
This page lists
10
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.